Evidence summary for pain management during retinopathy of prematurity screening

早产儿视网膜病变筛查期间疼痛管理的证据总结

阅读:1

Abstract

BACKGROUND: Retinopathy of prematurity (ROP) is one of the leading causes of childhood blindness. Routine ROP screening in high-risk preterm infants is a fundamental and effective measure to prevent ROP; however, this screening process could cause pain to infants. This study aims to summarize the best evidence for pain management during ROP screening and provide a reference for the clinical practice of medical staff. METHODS: We systematically searched the literature on pain management during ROP screening, including clinical practice guidelines, evidence summaries, systematic reviews, meta-analyses, clinical decision support tools, and expert consensus statements. The search period was from inception to 31 October 2024. Four reviewers independently evaluated the quality of guidelines, and two reviewers independently assessed the quality of systematic reviews and expert consensus statements. Subsequently, evidence was extracted and graded. RESULTS: Eighteen articles were included: six guidelines, three clinical decision support tools, six systematic reviews, and three expert consensus statements. 92 pieces of evidence were extracted and categorized into five dimensions: multidisciplinary pain management teams for ROP screening, pain assessment, non-pharmacological interventions, pharmacological interventions and pain documentation. Twenty-five evidence-based recommendations were finally formulated. CONCLUSION: The best evidence-based strategies for pain management during ROP screening in preterm infants provide actionable guidance for clinical practice. Medical staff should strengthen training in neonatal pain management and implement combined pharmacological and non-pharmacological interventions to alleviate procedural pain during ROP screening.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。